Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Di
Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing
What was tested
Treatment tested
- Rituximab
B-lymphocyte antigen CD20 binding agent
Compared with
- Ocrelizumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
The primary endpoint is to determine the difference in efficacy and safety between rituximab and ocrelizumab according to the following criteria:
Safety
Other measures (1)
•Proportion of patients with 6-months confirmed disability progression (6M-CDP) as measured by the Expanded disability status scale (EDSS) from baseline to month 24. CDP-EDSS defined as an increase of one point in the EDSS score confirmed after 6 months, with an absence of relapse at the time of assessment.
Disability progressionRelapses
Papers
Results
Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis.N Engl J Med · 2026
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogeni
Phase 2 · Not yet recruiting
Still running
- Switch to Ofatumumab and Level of Immunoglobulins
Recruiting
Still running
- Non-interventional Study of Subcutaneous Ocrelizumab in Persons With R
Recruiting
Still running
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Mult
Recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
History
- In scope changed from true to false
Started
Jun 2020